Comparing the current results to its competitors, Dermata Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 2.67 %, recorded in the same quarter.
Dermata Therapeutics Inc 's Comment on Competition and Industry Peers
The company competes with established consumer skincare brands including Neutrogena®, Proactiv®, Clean & Clear®, PanOxyl®, La Roche-Posay®, CeraVe®, and Differin®, many of which are owned or distributed by large multinational consumer health companies. These competitors have extensive retail distribution, strong brand recognition, substantial marketing resources, and greater manufacturing, financial, research and development, and over-the-counter marketing experience. The company also faces competition from digital-first and direct-to-consumer skincare companies such as Curology®, Apostrophe®, and Hims & Hers®, some of which offer prescription-based acne treatments alongside over-the-counter products. These competitors may develop superior products and maintain competitive advantages that could render the company's products obsolete or economically nonviable.
AbbVie Inc operates primarily as a global biopharmaceutical company, focusing on the research, development, manufacturing, and commercialization of advanced therapies and medications in critical areas such as immunology, oncology, neuroscience, and virology. The company aims to improve patient outcomes and address unmet medical needs by leveraging its scientific expertise and capabilities while providing value to stakeholders in the healthcare industry.
Gt Biopharma Inc's business model revolves around developing innovative immunotherapies for the treatment of various cancers. The company focuses on harnessing the power of the immune system to target and eliminate cancer cells through its proprietary technology platform. Gt Biopharma Inc aims to advance its therapies through clinical trials and ultimately commercialize them for the benefit of patients worldwide.
Incyte Corporation is a biopharmaceutical company that primarily focuses on the research, development, and commercialization of innovative medicines targeting oncology and serious inflammatory conditions. Their business model emphasizes robust R&D investments to discover potential drug candidates, often engaging in collaborations with other organizations to enhance their development capabilities. Incyte leverages its extensive intellectual property portfolio to protect and maximize the value of its therapeutic advancements in the market.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Sources:
Dermata Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Dermata Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
